INDUSTRYWEEK: Addressing Test Shortfall

Empirical Bioscience recently announced that its QuantiTASE and QuantiTASE PLUS One Step RT-qPCR RT-qPCR kits have successfully tested in assays using EUA authorized qPCR detection kits following the CDC testing protocol.

The test amplifies and identifies genetic material from the SARS-CoV-2 virus that causes COVID-19 in one step. The QuantiTASE RT-qPCR Assay Kits works by converting the CoV-2 RNA into DNA and amplifying to detect the presence of pathogenic material in patient samples.

The kit operates on most existing laboratory testing equipment in the United States, and it includes all the required RT-qPCR reaction reagents needed to run a COVID-19 test. It also meets the performance requirements for nCoV-2 testing established by the Centers for Disease Control (CDC) when used in accordance with CDC guidelines and in conjunction with an approved detection kit.

Designed to be comparable to other one step Rt-qPCR kits on the market, Empirical developed its test to supplement the current shortfall in the market for use in various testing facilities with minimal disruption to existing processes. Empirical has adjusted its production rates. “We are ramping up our production capacity from 50,000 kits a week to 100,000 a week,” said Empirical Bioscience President Des O’Farrell.

Continue reading at IndustryWeek…